Prognostic value of serum soluble Fas in patients with locally advanced unresectable rectal cancer receiving concurrent chemoradiotherapy

Journal of Zhejiang University: Science B

Volumn 11, Issue 12, 2010, Pages 912-917

  Liang, Qi Lian ^a   Li, Zhou Yu ^a   Chen, Guo Qiang ^a   Lai, Zhen Nan ^a   Wang, Bi Rong ^b   Huang, Jie ^a  

^a GUANGDONG MEDICAL UNIVERSITY   (China)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Concurrent chemoradiotherapy; Prognosis; Rectal cancer; Soluble Fas (sFas)

Indexed keywords

FAS ANTIGEN; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; SOLUBLE FAS ANTIGEN; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMORADIOTHERAPY; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; INOPERABLE CANCER; LIVER DISEASE; LOCALLY ADVANCED UNRESECTABLE RECTUM CANCER; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NERVE CACESTHESIA; NEUROPATHY; NEUTROPENIA; PATIENT MONITORING; PRIORITY JOURNAL; PROCTITIS; PROGNOSIS; PROTEIN BLOOD LEVEL; RADIATION INJURY; RADIATION PROCTITIS; RADIATION SAFETY; RECTUM CANCER; STOMATITIS; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR VOLUME; BLOOD; MIDDLE AGED; MORTALITY; PATHOLOGY; RECTUM TUMOR;

ADULT; AGED; ANTIGENS, CD95; COMBINED MODALITY THERAPY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RECTAL NEOPLASMS;

EID: 79953014607     PISSN: 16731581     EISSN: 18621783     Source Type: Journal    
DOI: 10.1631/jzus.B1000277     Document Type: Article

References (27)

1. Abbasova, S.G., Vysotskii, M.M., Ovchinnikova, L.K., Obusheva, M.N., Digaeva, M.A., Britvin, T.A., Bahoeva, K.A., Karabekova, Z.K., Kazantzeva, I.A., Mamedov, U.R., et al., 2009. Cancer and soluble Fas. Bull. Exp. Biol. Med., 148(4):638-642. [doi:10.1007/s10517-010-0784-8]
2. Bewick, M., Conlon, M., Parissenti, A.M., Lee, H., Zhang, L., Glück, S., Lafrenie, R.M., 2001. Soluble Fas (CD95) is a prognostic factor in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous stem cell transplantation. J. Hematother. Stem. Cell. Res., 10(6):759-768. [doi:10.1089/152581601317210854] (Pubitemid 34081304)
3. Boroumand-Noughabi, S., Sima, H.R., Ghaffarzadehgan, K., Jafarzadeh, M., Raziee, H.R., Hosseinnezhad, H., Moaven, O., Rajabi-Mashhadi, M.T., Azarian, A.A., Mashhadinejad, M., et al., 2010. Soluble Fas might serve as a diagnostic tool for gastric adenocarcinoma. BMC Cancer, 10(1):275. [doi:10.1186/1471-2407- 10-275]
4. Bosset, J.F., Calais, G., Daban, A., Berger, C., Radosevic-Jelic, L., Maingon, P., Bardet, E., Pierart, M., Briffaux, A., EORTC Radiotherapy Group, 2004. Preoperative chemoradiotherapy versus preoperative radiotherapy in rectal cancer patients: Assessment of acute toxicity and treatment compliance. Report of the 22921 randomised trial conducted by the EORTC Radiotherapy Group. Eur. J. Cancer, 40(2):219-224. [doi:10.1016/j.ejca.2003.09.032]
5. Cascino, I., Fiucci, G., Papoff, G., Ruberti, G., 1995. Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. J. Immunol., 154(6):2706-2713.
6. Chaudhry, P., Srinivasan, R., Patel, F.D., Gopalan, S., Majumdar, S., 2008. Serum soluble Fas levels and prediction of response to platinum-based chemotherapy in epithelial ovarian cancer. Int. J. Cancer, 122(8):1716-1721. [doi:10. 1002/ijc.23213]
7. Debatin, K.M., Krammer, P.H., 2004. Death receptors in chemotherapy and cancer. Oncogene, 23(16):2950-2966. [doi:10.1038/sj.onc.1207558] (Pubitemid 38638855)
8. Eichhorst, S.T., Müerköster, S., Weigand, M.A., Krammer, P.H., 2001. The chemotherapeutic drug 5-fluorouracil induces apoptosis in mouse thymocytes in vivo via activation of the CD95 (APO-1/Fas) system. Cancer Res., 61(1):243-248. (Pubitemid 32095724)
9. Gratas, C., Tohma, Y., Barnas, C., Taniere, P., Hainaut, P., Ohgaki, H., 1998. Up-regulation of Fas (APO-1/CD95) ligand and down-regulation of Fas expression in human esophageal cancer. Cancer Res., 58(10):2057-2062. (Pubitemid 28232883)
10. Griffith, T.S., Brunner, T., Fletcher, S.M., Green, D.R., Ferguson, T.A., 1995. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science, 270(5239): 1189-1192. [doi:10.1126/science.270.5239.1189]
11. Havenga, K., Enker, W.E., Norstein, J., Moriya, Y., Heald, R.J., van Houwelingen, H.C., van de Velde, C.J., 1999. Improved survival and local control after total mesorectal excision or D3 lymphadenectomy in the treatment of primary rectal cancer: An international analysis of 1411 patients. Eur. J. Surg. Oncol., 25(4):368-374. [doi:10. 1053/ejso.1999.0659] (Pubitemid 29364222)
12. Jodo, S., Kobayashi, S., Nakajima, Y., Matsunaga, T., Nakayama, N., Ogura, N., Kayagaki, N., Okumura, K., Koike, T., 1998. Elevated serum levels of soluble Fas/APO-1 (CD95) in patients with hepatocellular carcinoma. Clin. Exp. Immunol., 112(2):166-171. [doi:10.1046/j.1365-22 49.1998.00569.x] (Pubitemid 28266673)
13. Kachnic, L.A., 2007. Adjuvant chemoradiation for localized rectal cancer: Current trends and future directions. Gastrointest. Cancer Res., 1(4 Suppl. 2):S64-S72.
14. Kimura, K., Gelmann, E.P., 2000. Tumor necrosis factor-alpha and Fas activate complementary Fas-associated death domain-dependent pathways that enhance apoptosis induced by gamma-irradiation. J. Biol. Chem., 275(12): 8610-8617. [doi:10.1074/jbc.275.12.8610] (Pubitemid 30180210)
15. Klautke, G., Feyerherd, P., Ludwig, K., Prall, F., Foitzik, T., Fietkau, R., 2005. Intensified concurrent chemoradiotherapy with 5-fluorouracil and irinotecan as neoadjuvant treatment in patients with locally advanced rectal cancer. Br. J. Cancer, 92(7):1215-1220. [doi:10.1038/sj.bjc.66 02492] (Pubitemid 40604394)
16. Kushlinskii, N.E., Britvin, T.A., Abbasova, S.G., Perevoshchikov, A.G., Prorokov, V.V., Kostanyan, I.A., Knysh, V.I., Lipkin, V.M., 2001. Soluble Fas antigen in the serum of patients with colon cancer. Bull. Exp. Biol. Med., 131(4):361-363. [doi:10.1023/A:1017908320634] (Pubitemid 33149834)
17. Liang, Q.L., Pan, D.C., Yin, Z.M., Liu, G.X., Yang, Q., Xie, J.R., Cai, L.Z., Fu, Y.W., 2002. Clinical value of serum soluble Apo-1/Fas for predicting biological behaviors and prognosis of gastric carcinoma. Ai Zheng, 21(2):174-176 (in Chinese).
18. Liang, Q.L., Wang, B.R., Li, G.H., 2009. DcR3 and survivin are highly expressed in colorectal carcinoma and closely correlated to its clinicopathologic parameters. J. Zhejiang Univ.-Sci. B, 10(9):675-682. [doi:10.1631/jzus.B0920077]
19. Natoli, G., Ianni, A., Costanzo, A., de Petrillo, G., Ilari, I., Chirillo, P., Balsano, C., Levrero, M., 1995. Resistance to Fas-mediated apoptosis in human hepatoma cells. Oncogene, 11(6):1157-1164.
20. Naumnik, W., Izycki, T., Ossolinska, M., Chyczewska, E., 2007. Serum levels of sFas and sFasL during chemotherapy of lung cancer. Exp. Oncol., 29(2):132-136. (Pubitemid 47310508)
21. Nesbakken, A., Nygaard, K., Westerheim, O., Mala, T., Lunde, O.C., 2002. Local recurrence after mesorectal excision for rectal cancer. Eur. J. Surg. Oncol., 28(2):126-134. [doi:10. 1053/ejso.2001.1231] (Pubitemid 35023653)
22. Pan, G., Ahn, E.Y., Chen, Y., Feng, G., Reddy, V., Jhala, N.C., McDonald, J.M., 2007. Reciprocal co-expression of Fas and Fas ligand in human cholangiocarcinoma. Int. J. Oncol., 31(4):843-850.
23. Petak, I., Tillman, D.M., Harwood, F.G., Mihalik, R., Houghton, J.A., 2000. Fas-dependent and independent mechanisms of cell death following DNA damage in human colon carcinoma cells. Cancer Res., 60(10): 2643-2650. (Pubitemid 30318239)
24. Shimizu, M., Kondo, M., Ito, Y., Kume, H., Suzuki, R., Yamaki, K., 2005. Soluble Fas and Fas ligand provide new information on metastasis and response to chemotherapy in SCLC patients. Cancer Detect. Prev., 29(2): 175-180. [doi:10.1016/j.cdp.2004.09.001]
25. Spindler, K.L., Nielsen, J.N., Lindebjerg, J., Brandslund, I., Jakobsen, A., 2006. Prediction of response to chemoradiation in rectal cancer by a gene polymorphism in the epidermal growth factor receptor promoter region. Int. J. Radiat. Oncol. Biol. Phys., 66(2):500-504. [doi:10.1016/j. ijrobp.2006.03.030] (Pubitemid 44332722)
26. Suda, T., Takahashi, T., Golstein, P., Nagata, S., 1993. Molecular cloning and expression of the Fas ligand a novel member of the tumor necrosis factor family. Cell, 75(6): 1169-1178. [doi:10.1016/0092-8674(93)90326-L] (Pubitemid 24006113)
27. Zhu, Q., Han, S.X., Li, M.Z., Su, B.S., Ma, J.L., 2006. The expression of Fas, p53, Bcl-2 and cervix carcinoma cell apoptosis during radiotherapy. Modern Oncol., 14(6): 730-732 (in Chinese).